Impact of response to thalidomide-, lenalidomide- or bortezomib-containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation

被引：5
|
作者：
Awan, F. T. [1 ]
Osman, S. [2 ]
Kochuparambil, S. T. [1 ]
Gibson, L. [2 ]
Remick, S. C. [2 ]
Abraham, J. [2 ]
Craig, M. [2 ]
Jillella, A. [1 ]
Hamadani, M. [2 ]
机构：
[1] Med Coll Georgia, Dept Internal Med, Div Hematol Oncol, Augusta, GA 30912 USA
[2] W Virginia Univ, MBRCC, Osborn Hematopoiet Malignancy & Transplantat Prog, Morgantown, WV 26506 USA
来源：
BONE MARROW TRANSPLANTATION | 2012年 / 47卷 / 01期
关键词：
BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; HIGH-DOSE MELPHALAN; AUTOTRANSPLANTATION; CHEMOTHERAPY; TRIAL;
D O I：
10.1038/bmt.2011.18
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：146 / 148
页数：3
相关论文
共 50 条
  • [41] Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients
    Shah, N.
    Weber, D.
    Orlowski, R.
    Wang, M.
    Thomas, S. K.
    Richards, T.
    Giralt, S.
    Qazilbash, M.
    Alexanian, R.
    Shah, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Second Line Treatment in Patients with Multiple Myeloma Progressing after Bortezomib, Lenalidomide, Dexamethasone Induction, Autologous Transplant and Lenalidomide Maintenance
    Pasvolsky, Oren
    Milton, Denai R.
    Tanner, Mark R.
    Bashir, Qaiser
    Srour, Samer A.
    Saini, Neeraj Y.
    Lin, Paul
    Siddiqui, Umer R.
    Khan, Hina N.
    Ramdial, Jeremy
    Nieto, Yago
    Tang, Guilin
    Lakhani, Kiran
    Aljawai, Yosra M.
    Kebriaei, Partow
    Lee, Hans C.
    Patel, Krina K.
    Thomas, Sheeba K.
    Orlowski, Robert Z.
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BLOOD, 2024, 144 : 7018 - 7019
  • [43] Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
    Osman, Salman
    Kanate, Abraham Sebastian
    Bunner, Pamela
    Leadmon, Sonia
    Tse, William
    Cumpston, Aaron
    Gibson, Laura
    Remick, Scot
    Abraham, Jame
    Craig, Michael
    Hamadani, Sayed Mehdi
    BLOOD, 2010, 116 (21) : 578 - 578
  • [44] A Response Adapted Approach to Induction Treatment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
    Shah, Gunjan L.
    Weltz, Jonathan
    Zhou, Quin
    Devlin, Sean M.
    Landau, Heather
    Chung, David J.
    Lendvai, Nikoletta
    Lesokhin, Alexander M.
    Korde, Neha
    Koehne, Guenther
    Giralt, Sergio A.
    Hassoun, Hani
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S40 - S41
  • [45] Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation
    Chakraborty, Rajshekhar
    Muchtar, Eli
    Kumar, Shaji K.
    Buadi, Francis K.
    Dingli, David
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Hogan, William J.
    Kapoor, Prashant
    Lacy, Martha Q.
    Leung, Nelson
    Warsame, Rahma
    Kourelis, Taxiarchis
    Gonsalves, Wilson
    Gertz, Morie A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (01) : 71 - 77
  • [46] Intensive therapy with bortezomib and melphalan and autologous stem cell transplantation for patients with multiple myeloma
    Luo, Y.
    Tan, Y.
    He, J.
    Shi, J.
    Wu, W.
    Han, X.
    Zheng, G.
    Wei, G.
    Zheng, W.
    Ye, X.
    Cai, Z.
    Huang, H.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S264 - S264
  • [47] Consolidation and maintenance therapy with bortezomib for Vietnamese patients with multiple myeloma after autologous transplantation**
    Vu, Minh Phuong
    Kieu, Thi Van Oanh
    Vu, Hoang
    LEUKEMIA RESEARCH REPORTS, 2023, 19
  • [48] Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients
    Shuichiro Takashima
    Toshihiro Miyamoto
    Masanori Kadowaki
    Yoshikiyo Ito
    Takatoshi Aoki
    Ken Takase
    Takahiro Shima
    Goichi Yoshimoto
    Koji Kato
    Tsuyoshi Muta
    Motoaki Shiratsuchi
    Katsuto Takenaka
    Hiromi Iwasaki
    Takanori Teshima
    Tomohiko Kamimura
    Koichi Akashi
    International Journal of Hematology, 2014, 100 : 159 - 164
  • [49] Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma
    Bumma, Naresh
    Dhakal, Binod
    Fraser, Raphael
    Estrada-Merly, Noel
    Anderson, Kenneth
    Freytes, Cesar O.
    Hildebrandt, Gerhard C.
    Holmberg, Leona
    Krem, Maxwell M.
    Lee, Cindy
    Lekakis, Lazaros
    Lazarus, Hillard M.
    Mian, Hira
    Murthy, Hemant S.
    Nathan, Sunita
    Nishihori, Taiga
    Parrondo, Ricardo
    Patel, Sagar S.
    Solh, Melhem
    Strouse, Christopher
    Vesole, David H.
    Kumar, Shaji
    Qazilbash, Muzaffar H.
    Shah, Nina
    D'Souza, Anita
    Sidana, Surbhi
    CANCER, 2023, 129 (14) : 2179 - 2191
  • [50] Impact of Diabetes Mellitus on Outcomes of Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma in the US
    Siwakoti, Krishmita
    Giri, Smith
    Bhatt, Vijay
    DIABETES, 2018, 67
12345